Diffuse large B-cell lymphoma is associated with varying outcomes, and disparities exist within high-risk disease. Prognostication with the International Prognostic Index anticipates patient outcomes, provides risk stratification, and guides treatment. We used a national database to compare the treatment outcomes from academic and nonacademic centers. We found improved overall survival in each risk category at academic centers.
|Original language||English (US)|
|Journal||Clinical Lymphoma, Myeloma and Leukemia|
|State||Published - Apr 2020|
- High risk
ASJC Scopus subject areas
- Cancer Research